{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:37:31Z","timestamp":1793489851235,"version":"4.5.0"},"reference-count":35,"publisher":"Japanese Society of Toxicology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2131\/jts.42.641","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T22:19:41Z","timestamp":1505254781000},"page":"641-650","source":"Crossref","is-referenced-by-count":6,"title":["A cell-based assay using HepaRG cells for predicting drug-induced phospholipidosis"],"prefix":"10.2131","volume":"42","author":[{"given":"Takafumi","family":"Tomida","sequence":"first","affiliation":[{"name":"Pharmacokinetics and Safety Department, Drug Research Center, Kyoto Research Center, Kaken Pharmaceutical Co., LTD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Ishimura","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Safety Department, Drug Research Center, Kyoto Research Center, Kaken Pharmaceutical Co., LTD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iwaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Kindai University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Anderson, N. and Borlak, J. (2006): Drug-induced phospholipidosis. FEBS Lett., <b>580<\/b>, 5533-5540.","DOI":"10.1016\/j.febslet.2006.08.061"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Aninat, C., Piton, A., Glaise, D., Le Charpentier, T., Langou\u00ebt, S., Morel, F., Guguen-Guillouzo, C. and Guillouzo, A. (2006): Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos., <b>34<\/b>, 75-83.","DOI":"10.1124\/dmd.105.006759"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Anth\u00e9rieu, S., Chesn\u00e9, C., Li, R., Guguen-Guillouzo, C. and Guillouzo, A. (2012): Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol. In Vitro, <b>26<\/b>, 1278-1285.","DOI":"10.1016\/j.tiv.2012.05.008"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Anth\u00e9rieu, S., Rogue, A., Fromenty, B., Guillouzo, A. and Robin, M.A. (2011): Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology,<b> 53<\/b>, 1895-1905.","DOI":"10.1002\/hep.24290"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Bauch, C., Bevan, S., Woodhouse, H., Dilworth, C. and Walker, P. (2015): Predicting<i> in vivo<\/i> phospholipidosis-inducing potential of drugs by a combined high content screening and<i> in silico<\/i> modelling approach. Toxicol. In Vitro, <b>29<\/b>, 621-630.","DOI":"10.1016\/j.tiv.2015.01.014"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Bhandari, N., Figueroa, D.J., Lawrence, J.W. and Gerhold, D.L. (2008): Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE. Assay Drug Dev. Technol., <b>6<\/b>, 407-419.","DOI":"10.1089\/adt.2007.119"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Donato, M.T., Mart\u00ednez-Romero, A., Jim\u00e9nez, N., Negro, A., Herrera, G., Castell, J.V., O&apos;Connor, J.E. and G\u00f3mez-Lech\u00f3n, M.J. (2009): Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem. Biol. Interact., <b>181<\/b>, 417-423.","DOI":"10.1016\/j.cbi.2009.07.019"},{"key":"8","unstructured":"Drenckhahn, D., Kleine, L. and L\u00fcllmann-Rauch, R. (1976): Lysosomal alterations in cultured macrophages exposed to anorexigenic and psychotropic drugs. Lab. Invest., <b>35<\/b>, 116-123."},{"key":"9","doi-asserted-by":"crossref","unstructured":"Garside, H., Marcoe, K.F., Chesnut-Speelman, J., Foster, A.J., Muthas, D., Kenna, J.G., Warrior, U., Bowes, J. and Baumgartner, J. (2014): Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes. Toxicol. In Vitro, <b>28<\/b>, 171-181.","DOI":"10.1016\/j.tiv.2013.10.015"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C. and Guguen-Guillouzo, C. (2002): Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. USA, <b>99<\/b>, 15655-15660.","DOI":"10.1073\/pnas.232137699"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Guguen-Guillouzo, C. and Guillouzo, A. (2010): General review on <i>in vitro<\/i> hepatocyte models and their applications. Methods Mol. Biol., <b>640<\/b>, 1-40.","DOI":"10.1007\/978-1-60761-688-7_1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Guillouzo, A., Corlu, A., Aninat, C., Glaise, D., Morel, F. and Guguen-Guillouzo, C. (2007): The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact., <b>168<\/b>, 66-73.","DOI":"10.1016\/j.cbi.2006.12.003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Gum, R.J., Hickman, D., Fagerland, J.A., Heindel, M.A., Gagne, G.D., Schmidt, J.M., Michaelides, M.R., Davidsen, S.K. and Ulrich, R.G. (2001): Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes(1). Biochem. Pharmacol., <b>62<\/b>, 1661-1673.","DOI":"10.1016\/S0006-2952(01)00823-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Lech\u00f3n, M.J., Tolosa, L., Castell, J.V. and Donato, M.T. (2010): Mechanism-based selection of compounds for the development of innovative <i>in vitro<\/i> approaches to hepatotoxicity studies in the LIINTOP project. Toxicol. In Vitro, <b>24<\/b>, 1879-1889.","DOI":"10.1016\/j.tiv.2010.07.018"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Hanumegowda, U.M., Wenke, G., Regueiro-Ren, A., Yordanova, R., Corradi, J.P. and Adams, S.P. (2010): Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. Chem. Res. Toxicol., <b>23<\/b>, 749-755.","DOI":"10.1021\/tx9003825"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Kasahara, T., Tomita, K., Murano, H., Harada, T., Tsubakimoto, K., Ogihara, T., Ohnishi, S. and Kakinuma, C. (2006): Establishment of an<i> in vitro<\/i> high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol. Sci., <b>90<\/b>, 133-141.","DOI":"10.1093\/toxsci\/kfj067"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Lambert, C.B., Spire, C., Claude, N. and Guillouzo, A. (2009): Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol. Appl. Pharmacol., <b>234<\/b>, 345-360.","DOI":"10.1016\/j.taap.2008.11.008"},{"key":"18","doi-asserted-by":"crossref","unstructured":"L\u00fcllmann, H., L\u00fcllmann-Rauch, R. and Wassermann, O. (1975): Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit. Rev. Toxicol., <b>4<\/b>, 185-218.","DOI":"10.1080\/10408447509164014"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Matsuzawa, Y., Yamamoto, A., Adachi, S. and Nishikawa, M. (1977): Studies on drug-induced lipidosis. VIII. Correlation between drug accumulation and acidic phospholipids. J. Biochem., <b>82<\/b>, 1369-1377.","DOI":"10.1093\/oxfordjournals.jbchem.a131824"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Morelli, J.K., Buehrle, M., Pognan, F., Barone, L.R., Fieles, W. and Ciaccio, P.J. (2006): Validation of an<i> in vitro<\/i> screen for phospholipidosis using a high-content biology platform. Cell Biol. Toxicol., <b>22<\/b>, 15-27.","DOI":"10.1007\/s10565-006-0176-z"},{"key":"21","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, P.J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C.M., Slaughter, M.R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., Brain, P. and Hougham, C. (2006): High concordance of drug-induced human hepatotoxicity with <i>in vitro<\/i> cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol., <b>80<\/b>, 580-604.","DOI":"10.1007\/s00204-006-0091-3"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Olesen, O.V. and Linnet, K. (1997): Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology, <b>55<\/b>, 235-243.","DOI":"10.1159\/000139533"},{"key":"23","unstructured":"Ploemen, J.P., Kelder, J., Hafmans, T., van de Sandt, H., van Burgsteden, J.A., Saleminki, P.J. and van Esch, E. (2004): Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. Exp. Toxicol. Pathol., <b>55<\/b>, 347-355."},{"key":"24","doi-asserted-by":"crossref","unstructured":"Reasor, M.J., Hastings, K.L. and Ulrich, R.G. (2006): Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf., <b>5<\/b>, 567-583.","DOI":"10.1517\/14740338.5.4.567"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Shah, F., Leung, L., Barton, H.A., Will, Y., Rodrigues, A.D., Greene, N. and Aleo, M.D. (2015): Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic <i>in vitro<\/i> Assays. Toxicol. Sci., <b>147<\/b>, 500-514.","DOI":"10.1093\/toxsci\/kfv152"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Su, P., Coutts, R.T., Baker, G.B. and Daneshtalab, M. (1993): Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. Xenobiotica, <b>23<\/b>, 1289-1298.","DOI":"10.3109\/00498259309059439"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Takagi, M., Sanoh, S., Santoh, M., Ejiri, Y., Kotake, Y. and Ohta, S. (2016): Detection of metabolic activation leading to drug-induced phospholipidosis in rat hepatocyte spheroids. J. Toxicol. Sci., <b>41<\/b>, 155-164.","DOI":"10.2131\/jts.41.155"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Tilmant, K., Gerets, H.H., Dhalluin, S., Hanon, E., Depelchin, O., Cossu-Leguille, C., Vasseur, P. and Atienzar, F. A. (2011): Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis. Toxicol. In Vitro, <b>25<\/b>, 1414-1424.","DOI":"10.1016\/j.tiv.2011.04.010"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Tomida, T., Okamura, H., Satsukawa, M., Yokoi, T. and Konno, Y. (2015): Multiparametric assay using HepaRG cells for predicting drug-induced liver injury. Toxicol. Lett., <b>236<\/b>, 16-24.","DOI":"10.1016\/j.toxlet.2015.04.014"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Tomida, T., Okamura, H., Yokoi, T. and Konno, Y. (2017): A modified multiparametric assay using HepaRG cells for predicting the degree of drug-induced liver injury risk. J. Appl. Toxicol., <b>37<\/b>, 382-390.","DOI":"10.1002\/jat.3371"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Usui, T., Mise, M., Hashizume, T., Yabuki, M. and Komuro, S. (2009): Evaluation of the potential for drug-induced liver injury based on <i>in vitro<\/i> covalent binding to human liver proteins. Drug Metab. Dispos., <b>37<\/b>, 2383-2392.","DOI":"10.1124\/dmd.109.028860"},{"key":"32","doi-asserted-by":"crossref","unstructured":"van de Water, F.M., Havinga, J., Ravesloot, W.T., Horbach, G.J. and Schoonen, W.G. (2011): High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of <i>in vivo<\/i> based phospholipidosis. Toxicol. In Vitro,<b> 25<\/b>, 1870-1882.","DOI":"10.1016\/j.tiv.2011.05.026"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Xu, J.J., Henstock, P.V., Dunn, M.C., Smith, A.R., Chabot, J.R. and de Graaf, D. (2008): Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci., <b>105<\/b>, 97-105.","DOI":"10.1093\/toxsci\/kfn109"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Yumibe, N., Huie, K., Chen, K.J., Snow, M., Clement, R.P. and Cayen, M.N. (1996): Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem. Pharmacol.,<b> 51<\/b>, 165-172.","DOI":"10.1016\/0006-2952(95)02169-8"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Zhou, L., Geraci, G., Hess, S., Yang, L., Wang, J. and Argikar, U. (2011): Predicting phospholipidosis: a fluorescence noncell based <i>in vitro<\/i> assay for the determination of drug-phospholipid complex formation in early drug discovery. Anal. Chem., <b>83<\/b>, 6980-6987.","DOI":"10.1021\/ac200683k"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/42\/5\/42_641\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T11:34:35Z","timestamp":1570102475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/42\/5\/42_641\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.42.641","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}